Live
FierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assetsEndpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departsEndpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI modelsCellChloroplast sunscreening by protein condensates confers high-light toleranceFierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 testEndpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 studyRoche MediaPartnering for Sustainable Healthcare: Roche Stands with Taiwan to Build an Innovation-Friendly Biomedical Ecosystem - Taiwan Business TOPICSBioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haulEndpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugsEndpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotecheLifeConstraints on the G1/S transition pathway may favor selection of multicellularity as a passenger phenotypeFierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game
Cell Jan 25, 2026

PIKFYVE inhibition mitigates disease in models of diverse forms of ALS

PIKFYVE inhibition mitigates disease in models of diverse forms of ALS

Original
Body unavailable. Use the original source.